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Insulin stimulates the translocation of the glucose transporter
GLUT4 from intracellular vesicles to the plasma membrane. In the
present study we have conducted a comprehensive proteomic anal-
ysis of affinity-purified GLUT4 vesicles from 3T3-L1 adipocytes to
discover potential regulators of GLUT4 trafficking. In addition to
previously identified components of GLUT4 storage vesicles
including the insulin-regulated aminopeptidase insulin-regulated
aminopeptidase and the vesicle soluble N-ethylmaleimide factor
attachment protein (v-SNARE) VAMP2, we have identified three
new Rab proteins, Rab10, Rab11, and Rab14, on GLUT4 vesicles.
We have also found that the putative Rab GTPase-activating pro-
tein AS160 (Akt substrate of 160 kDa) is associated with GLUT4
vesicles in the basal state and dissociates in response to insulin. This
association is likely to be mediated by the cytosolic tail of insulin-
regulated aminopeptidase, which interacted both in vitro and in
vivowith AS160. Consistent with an inhibitory role of AS160 in the
basal state, reduced expression of AS160 in adipocytes using short
hairpin RNA increased plasma membrane levels of GLUT4 in an
insulin-independent manner. These findings support an important
role for AS160 in the insulin regulated trafficking of GLUT4.
Glucose transport into mammalian muscle and fat cells is an impor-
tant step in insulin action and is critical for the maintenance of glucose
homeostasis within the body (1). In mammalian muscle and fat cells,
insulin stimulation activates a phosphorylation cascade, which in turn
causes intracellular vesicles that contain the glucose transporter
GLUT4,4 to translocate to the plasmamembrane (PM) and fuse (2, 3). In
the basal stateGLUT4 is distributed between the endosomal system, the
trans-Golgi network (TGN), and a GLUT4 storage vesicle (GSV) com-
partment that is highly insulin-responsive (4–6).
The protein kinase Akt is activated in response to insulin and plays a
critical role in GLUT4 translocation (1, 7). However, the link between
the insulin signaling pathway and GLUT4 translocation is not fully
understood. The insulin-dependent movement of GLUT4 vesicles to
the PM is an Akt-independent process, and this is followed by an Akt-
dependent step likely involving the docking and fusion of vesicles with
the PM (7–9). The mechanism by which Akt controls the docking and
fusion of GLUT4 vesicles with the PM is not known. However, it was
previously shown that a Rab GTPase-activating protein (RabGAP)
known as AS160 is phosphorylated by Akt in response to insulin (10).
How AS160 functions in GLUT4 trafficking and its cognate Rab pro-
teins are not known. The role of a variety of Rab proteins in GLUT4
trafficking including Rab3d, Rab4, Rab5, and Rab11 has been examined
(11–16). However, although these Rab proteinsmay participate in some
aspects of GLUT4 trafficking, no compelling evidence for specific
involvement in the insulin-regulated trafficking of GLUT4 has been
found.
In this study we describe four key findings that add to our under-
standing of GLUT4 trafficking. Using mass spectrometry we have iden-
tified three Rab proteins on GLUT4 vesicles that could potentially be
substrates of AS160 and, thus, play an important role in insulin-regu-
lated glucose transport. In addition, we have shown that AS160 is pres-
ent onGLUT4 vesicles in the basal state and dissociateswith insulin.We
have gone on to show that the association of AS160 with GLUT4 vesi-
cles is mediated at least in part via a direct interaction with the cytosolic
tail of IRAP, and this interaction appears to be insulin-dependent. Fur-
thermore, a decrease in AS160 expression by shRNA leads to increased
levels of GLUT4 at the PM in the basal state. Together, these results
provide novel insights into the regulatory mechanism of insulin-stimu-
lated GLUT4 translocation.
EXPERIMENTAL PROCEDURES
Materials—3T3-L1 murine fibroblasts, C2C12 fibroblasts, and Chi-
nese hamster ovary (CHO) cells were purchased from the American
Type Culture Collection (ATCC, Manassas, VA). Dulbecco’s modified
Eagle’s medium and newborn calf serum were obtained from Invitro-
gen, Myoclone-Plus fetal calf serum from Trace Scientific (Melbourne,
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Australia), and antibiotics were from Invitrogen. Paraformaldehyde was
fromProSciTech (ThuringowaCentral, Australia). Insulinwas obtained
from Calbiochem, and bovine serum albumin from United States Bio-
chemical Corp. (Cleveland, OH). Bicinchoninic acid reagent, GF-2000
beads, Supersignal West Pico chemiluminescent substrate, and protein
G-agarose beads were from Pierce. Lipofectamine 2000 was from
Invitrogen. Centrifuge tubes (11 60mm) were from Beckman Instru-
ments. Polyvinylidene difluoride membrane was from Millipore (Bil-
lerica, MA). C18 Stagetips were from Proxeon Biosystems (Odense,
Denmark). Trypsin was from Promega (Madison, WI). Strong cation
exchange andC18 cartridges were fromMichrom (Auburn, CA).Magic
C18 material was from (Alltech, Deerfield, IL). Complete protease
inhibitor mixture tablets were from Roche Applied Science. All other
materials were obtained from Sigma. Antibodies were kindly provided
by Dr. Gwyn Gould (CI-MPR and CD-MPR, University of Glasgow,
Glasgow, UK), Dr. ClausMunck Peterson (sortilin,Weizmann Institute
of Science, Rehovot, Israel), Dr. P. Chavrier (Rab5 and Rab7, INSERM-
CNRS, Marseille, France), Dr. Robert Parton (Rab11, University of
Queensland, Brisbane, Australia), Dr. Bernad (PKL12, Campus de la
Universidad Autonoma de Madrid, Madrid, Spain), Dr. Castle
(SCAMP2 and SCAMP3, University of Virginia, USA), Dr. Wanjin
Hong (syntaxin 16, IMCB, Singapore), and Dr. Julian Mercer (ATP7A,
Deakin University, Burwood, Australia). Antibodies were purchased
from Santa Cruz Biotechnology (IRS-1; Santa Cruz, CA), Cayman
Chemical (CD36), BD Biosciences Pharmingen (Vti1b), Synaptic Sys-
tems (VAMP2, VAMP8, and mVps45; Goettingen, Germany), Zymed
Laboratories Inc.; San Francisco, CA (TfR), Sigma (FLAG M2), Trans-
duction Laboratories (syntaxin 6; Lexington, KY), and Berkeley Anti-
bodyCo., Inc. (HApeptide (16B12); Richmond, CA). Antibodies against
GLUT4 (17), syntaxin 4 (18), IRAP (5), Rab14 (19), and VAMP3 (18)
have been described previously. ALEXA 488 and Cy3-conjugated sec-
ondary antibodies were obtained from Molecular Probes (Leiden, The
Netherlands) or Jackson ImmunoResearch (West Grove, PA), respec-
tively. Horseradish peroxidase-conjugated secondary antibodies were
from Amersham Biosciences.
Production of a Rabbit AS160 Antibody—Rabbit polyclonal antibod-
ies against human AS160 (TBC1D4) were produced as previously
described (18) using a region of human AS160 from amino acids 621–
766 fused with GST. Serum from these rabbits was affinity-purified
using the AS160 antigen coupled to a GF-2000 column according to
manufacturer’s instructions.
Cell Culture—3T3-L1 fibroblasts, CHO, and C2C12 fibroblasts were
cultured as described previously (5). Briefly, cells were grown inDulbec-
co’s modified Eagle’s medium supplemented with 10% newborn calf
serum or fetal calf serum, 2 mM L-glutamine, 100 units/liter penicillin,
and 100 g/liter streptomycin at 37 °C in 10% CO2 and passaged at
60% confluence. In the case of 3T3-L1 fibroblasts, confluent cells were
differentiated into adipocytes and used between days 8 and 10 post-
differentiation and between passages 10 and 20. To establish basal con-
ditions before use, cells were incubated in serum-free Dulbecco’s mod-
ified Eagle’s medium for 2 h at 37 °C in 10% CO2.
Subcellular Fractionation of Adipocytes—3T3-L1 adipocyte fraction-
ation was carried out as described previously (5). Briefly, cells were
incubated for 2 h in Dulbecco’s modified Eagle’s medium containing 25
mM glucose at 37 °C and lysed using 12 passes through a 22-gauge nee-
dle followed by 6 passes through a 27-gauge needle in HES buffer (20
mM HEPES, 10 mM EDTA, 250 mM sucrose pH 7.4) containing Com-
plete protease inhibitor mixture and phosphatase inhibitors (2 mM
sodium orthovanadate, 1mM pyrophosphate, 1mM ammoniummolyb-
date, 10mM sodium fluoride) at 4 °C. The lysate was then centrifuged at
500  g for 10 min to remove unbroken cells and at 10,080  g for 12
min, 15,750 g for 17 min, and 175,000 g for 75 min at 4 °C to obtain
the PM, mitochondria and nuclei high density microsomal pellet con-
taining the endoplasmic reticulum and large endosomes, and the low
density microsomal (LDM) pellet which contained intracellular trans-
port vesicles and the majority of GLUT4 vesicles, respectively. The
LDM was then resuspended in PBS-containing inhibitors for use in
immunoprecipitations.
Cationic Colloidal Silica Plasma Membrane Isolation—Plasma
membranes were purified as per Chaney and Jacobson (21) with modi-
fications. Briefly, basal or insulin-stimulated 3T3-L1 adipocytes were
washed twice with ice-cold PBS and twice in ice-cold coating buffer (20
mM MES, 150 mM NaCl, 280 mM sorbitol, pH 5.0–5.5). Cationic silica
1% (stored as a 30% stock and diluted to 1% in coating buffer) was added
to the cells in coating buffer for 2 min on ice. Excess silica was removed
by washing once with ice-cold coating buffer. Sodium polyacrylate (1
mg/ml, pH6–6.5)was added to the cells in coating buffer and incubated
at 4 °C for 2 min. Cells were washed once in ice-cold coating buffer and
then washed withmodified HES (20mMHEPES, 250mM sucrose, 1 mM
dithiothreitol, 1 mMmagnesium acetate, 100mM potassium acetate, 0.5
mM zinc chloride, pH 7.4) at 4 °C and lysed as described above. Nyco-
denz (100%) in modified HES buffer was added to the lysate to a final
concentration of 50%. The lysate was layered onto 0.5 ml of 70% Nyco-
denz in modified HES and centrifuged in a swing-out rotor at 41,545
g for 20 min at 4 °C. The supernatant was discarded, and the pellet was
resuspended in 0.5 ml of modified HES buffer and centrifuged at 500
g for 5 min at 4 °C. The pellet was resuspended in SDS-PAGE sample
buffer and heated to 65 °C for 10 min. The sample was then centrifuged
at 10,000 g at 24 °C, and the supernatant was retained for analysis by
immunoblotting.
Immuno-isolation of GLUT4 Vesicles and Mass Spectrometry
Analysis—GLUT4 vesicles were immuno-isolated using the protocol of
Hashiramoto et al. (22) with the exception that either control mouse
IgG or the anti-GLUT4 monoclonal 1F8 was covalently coupled to
GF-2000 beads according tomanufacturer’s instructions. LDM (2.5mg)
was resuspended in 100 l of PBS and added to 50 l of both control
mouse IgG and 1F8 beads and incubated overnight with rotation at 4 °C
in the presence of 0.1% bovine serum albumin and PBS in a final volume
of 250 l. The beads were then washed 5 times with PBS, and the pro-
teins were eluted with 100% formic acid. The eluate was removed and
vacuum-dried. Ammonium bicarbonate (500 mM) was added to adjust
the pH to 8 and vacuum-dried again. Urea (10 M) and 5 mM dithiothre-
itol were then added, and samples were incubated at 37 °C for 1 h.
Cysteines were subsequently alkylated using a 10-fold molar excess of
iodoacetamide and incubated at 37 °C for 1 h. Proteins were digested by
the addition of modified trypsin (12.5 ng/l) in 100 mMNH4HCO3 and
incubated overnight at 37 °C. The digestionwas stopped by the addition
of 5% formic acid, and peptides were desalted using C18 Stagetips. Pep-
tideswere analyzed by two-dimensional liquid chromatography tandem
mass spectrometry using a CapLC high performance liquid chromatog-
raphy system (Waters, Milford, MA) by binding to a strong cation
exchange cartridge and sequential elution of the peptides using salt
steps of 5, 10, 15, 20, 25, 30, 40, 50, 75, 150, 300, 1000 mM ammonium
acetate. After each salt step eluted peptides were desalted on a capillary
C18 cartridge and resolved on a 100-mm 75-m C18 Magic reverse
phase analytical column with a flow rate of 200 nl/min. Peptides were
ionized by nanoelectrospray at 2.8 kV from the end of the column,
which was pulled to an inner diameter of 5 m by a P-2000 laser puller
(Sutter Instruments Co). Tandemmass spectral analysis was carried out
on a Waters (Milford, MA) quadrupole time-of-flight Ultima mass
AS160 and GLUT4 Trafficking
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spectrometer. A data-dependent acquisition method was used for all
experiments where precursor ions needed to have an intensity higher
than 10 counts and be in the2,3, or4 charge state.MS/MS spectra
were searched against a metazoan data base generated from Swiss-Prot
and Trembl containing 574734 sequences using Sequest (Thermo Elec-
tron Corporation, Waltham, MA). Peptides were counted as valid if in
the2 charge state they had a Xcorr value2 or in the3 charge state,
an Xcorr3.5. All peptides also needed a CN value greater than 0.08.
One missed cleavage per peptide was tolerated, and peptides could be
partially tryptic. Proteins identified by less than two peptides were val-
idated manually.
Immunoblotting—All samples were subjected to SDS-PAGE analysis
on 10% resolving gels according to Laemmli (23). Equal amounts of
protein were loaded for each sample in a single experiment, with 1–10
g per lane unless otherwise stated. Separated proteins were electro-
phoretically transferred to polyvinylidene difluoride membrane,
blocked with BB (2% nonfat skim milk in 0.1% Tween 20 in PBS), and
incubated with primary antibody in BB. After incubation, membranes
were washed 3 times in BB and incubated with horseradish peroxidase-
labeled secondary antibodies in BB. Proteins were visualized using
Supersignal West Pico chemiluminescent substrate and imaged using a
Versadoc 5000 imager (Bio-Rad).
Sucrose Gradient Flotation Experiments—LDM (165 l) obtained
from 3T3-L1 adipocytes as described above was mixed with 835 l of
70% sucrose solution inHES to a final concentration of 60% sucrose (24)
and placed in an 11 60-mm centrifuge tube overlaid with 1 ml of 50,
30, and 10% of sucrose and 0.4 ml of 5% sucrose. The sample was then
centrifuged for 18 h at 111,132 g in a Beckman SW61 swing-out rotor.
Fractions (0.4 ml) were collected from the bottom of the tube by gravi-
tational flow.
Confocal Laser Scanning Microscopy—3T3-L1 adipocytes were cul-
tured as described above on glass coverslips. The cells were serum-
depleted for 2 h at 37 °C, after which they were incubated in the absence
or presence of 200 nM insulin for 20 min. Cells were then fixed with 3%
paraformaldehyde in PBS. Fixed cells were washed with PBS, and free
aldehyde groups were quenched with 50 mM glycine in PBS. The cells
were then processed for immunolabeling by permeabilization and label-
ing in PBS containing 0.1% saponin and 2% bovine serum albumin using
standard procedures. Primary antibodies were detected with ALEXA-
488 or Cy3-conjugated secondary antibodies. Optical sections were
analyzed by confocal laser scanning microscopy using a Leica TCS SP
system. For double labeling, fluorophores were scanned separately and
overlaid using Adobe Photoshop software. Images were generated by
themaximumprojection of a stack sections from themiddle of each cell.
GLUT4 Recycling Experiments—3T3-L1 adipocytes expressing a
control shRNA or the AS160 shRNA and HA-GLUT4 were incubated
in the presence or absence of 100 nM insulin for 20 min. Anti-HA anti-
body (60 g/ml) was then added for 10 and 60 min. Subsequently the
cells were fixed, permeabilized, and incubated with a secondary Cy3-
conjugated anti-mouse antibody. Confocal laser scanning microscopy
was carried out as described above.
Transfection of C2C12 Cells and CHO Cells—C2C12 and CHO cells
were transiently transfected with DNA constructs for expression of
FLAG-tagged AS160 and the AS160 and control shRNA constructs
using Lipofectamine 2000 according to manufacturer’s instructions.
Immunoprecipitation and GST Pull-down of FLAG-tagged AS160—
FLAG-AS160-expressing CHO cells were lysed in extraction buffer (1%
Nonidet P-40, 137 mM sodium chloride, 10% glycerol, 25 mM Tris, pH
7.4), centrifuged at 18,000  g for 20 min, anti-FLAG antibody and
protein G beads were added to the supernatant and incubated for 2 h at
4 °Cwithmixing. The beads were then washed extensively and boiled in
SDS-PAGE sample buffer. For GST pull-downs, 100 g of lysate was
incubated with either GST alone or GST-IRAP1–109, GST-IRAP1–58,
GST-IRAP1–27, GST-GLUT4466–509, GST-VAMP21–94 coupled to
CNBr-activated-Sepharose 4B beads according to the manufacturer’s
instruction (Amersham Biosciences). Beads were washed extensively
and boiled in sample buffer.
Immunoprecipitation of Endogenous AS160 from 3T3-L1 Adipocytes—
The LDM fraction from basal or insulin-stimulated cells prepared as
described abovewas resuspended in IP buffer (60mM-octylglucoside, 1%
TritonX-100, 137mM sodium chloride, 10% glycerol, 25mMTris, pH 7.4),
incubated for 30min at 4 °C, and centrifuged at 200,000 g for 15min. An
aliquot of the supernatant (200 g) was incubated with either IgG or anti-
AS160 or anti IRAP antibodies coupled to CNBr-activated Sepharose 4B
beads overnight at 4 °C. Beads were washed four times in IP buffer without
-octylglucoside and twice in PBS and boiled in sample buffer.
Retroviral Transfection of shRNA—The shRNA for AS160 was cre-
ated using standard procedures with the target sequence 5-TAAC-
GAGGATGCCTTCTAC-3 as described previously (25). 3T3-L1
fibroblasts were infected with pBabe-puro-HA-GLUT4 retrovirus as
previously described (5). After 24 h cells were subsequently infected
using a similar protocol with pBabe-hygro-shRNA-AS160. Doubly
infected cells were selected in 2 g/ml puromyocin and 200 g/ml
hygromyocin. The surface HA-GLUT4 was measured in non-perme-
abilized adipocytes with anti-HA antibody as described previously (26).
Subsequently the cells were permeabilized and incubated with anti-
AS160 antibody. The quantification of fluorescence of single cells
infected with retrovirus expressing an shRNA against AS160 and HA-
GLUT4 was performed using the Leica confocal software. The confocal
images of the different conditions and cells were scanned with exactly
the same settings. A region of interest was set around each cell, and the
amount of fluorescence per unit area was determined for each channel
using the Leica confocal software.
RESULTS
Identification of GLUT4 Vesicle-associated Proteins in 3T3-L1
Adipocytes—To identify proteins that regulate GLUT4 trafficking, we
used two-dimensional liquid chromatography tandem mass spectrom-
etry to identify all of the proteins associated with immuno-isolated
GLUT4 vesicles. The immuno-isolation of GLUT4 vesicles was per-
formed using antibodies covalently attached to acrylamide beads (27).
To ensure that we ignored proteins that were isolated non-specifically,
we used a subtractive experimental design where we compared the pro-
tein composition of eluates from the control IgG versus that obtained
with the GLUT4 antibody. Only peptides identified using the GLUT4
antibody and not the control IgG in at least three separate experiments
were classified as valid.
The consensus of these experiments in 3T3-L1 adipocytes yielded 48
proteins (TABLE ONE), many of which are known to be involved in
vesicle trafficking. Details of peptides identified from each protein are
given in Supplemental Table 2. The proteins identified fall into five
classes; they are previously knownGLUT4 vesicle proteins (e.g. sortilin),
vesicle transport regulatory proteins (e.g. SNAREs), proteins from the
secretory pathway (e.g. cystatin c), recycling membrane proteins (e.g.
low density lipoprotein receptor), and proteins with unknown GLUT4
vesicle transport functions (e.g. ubiquitin, V-ATPase). Samples were
isolated from basal and insulin-stimulated adipocytes to determine
whether we could identify additional proteins that associated with
GLUT4 vesicles in an insulin-specific manner. However, no additional
proteins were identified in samples isolated from insulin-treated cells.
AS160 and GLUT4 Trafficking
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TABLE ONE
Summary of GLUT4 vesicle proteins identified bymass spectrometry from 3T3-L1 adipocytes
Proteins shown were the consensus of three separate experiments., no significant translocation;,2-fold translocation;,2-fold translocation. Summary of
localization of protein identified in GLUT4 vesicles was based on either the present study (†) or other published data.
AS160 and GLUT4 Trafficking
37806 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 280•NUMBER 45•NOVEMBER 11, 2005
 at UQ Library on October 10, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
We next wanted to determine which of these proteins might play a
functional regulatory role in GLUT4 trafficking or indeed determine
which proteins may be targeted with GLUT4 into insulin-responsive
vesicles. To accomplish this we divided these proteins into integral ver-
sus peripheral membrane proteins.
Characterization of Integral Membrane Proteins Found in GLUT4
Vesicles—It has previously been shown that GLUT4 is found in GSVs,
endosomes, and the TGN (28–30). Therefore, it was not surprising to
find a large number of endosomal and TGN-derived proteins in
immuno-isolated GLUT4 vesicles. To determine which of these were
localized to GSVs, we used two separate criteria. First, we examined
insulin-responsive movement to the PM, as this is a distinguishing fea-
ture of GSV constituents (31). Second, we performed co-localization
experiments to compare the intracellular distribution of each integral
membrane protein with GLUT4.
To quantify the insulin-dependent movement of proteins to the PM,
we developed a method to isolate highly purified plasma membranes
(21). Electron microscopy studies of these membranes revealed that
they contained large PM sheets with very little contamination from
other organelles (data not shown). The only other organelle we could
detect by electron microscopy was mitochondria. We were unable to
detect Golgi or endoplasmic reticulummembranes proteins in the puri-
fied PM fraction by immunoblotting (data not shown), which suggests
that this is a highly purified fraction. In contrast PM markers such as
syntaxin 4 or caveolin 1 were highly enriched in this fraction (data not
shown). We observed very little GLUT4 in the PM in the absence of
insulin, whereas after insulin stimulation there was a time-dependent
movement of GLUT4 to the PM, and this effect was inhibited by the
phosphatidylinositol 3-kinase inhibitor wortmannin (Fig. 1A). The level
of the t-SNARE syntaxin 4 in the PM remained constant under these
conditions (Fig. 1A). Among the integral membrane proteins examined
GLUT4, IRAP and VAMP2 exhibited the largest insulin-dependent
increase at the PM, showing 10-, 6-, and 2.5-fold increases, respectively
(Fig. 1B) (n 	 4). The protein that exhibited the next most significant
change with insulin was the TfR, showing a 1.5-fold increase in cell
surface levels (Fig. 1B). In contrast, other endosomal proteins such as
VAMP3 did not undergo any significant change in PM localization with
insulin. Consistent with previous studies (22, 32–35) we observed a
slight effect of insulin on PM levels of CI-MPR, CD-MPR, and sortilin,
but this was much lower than that observed for GLUT4, IRAP, or
VAMP2 (Fig. 1b). Intriguingly, the copper-transporting ATPase
(ATP7A), which was identified in GLUT4 vesicles and can translocate
to the plasmamembrane with copper-stimulation (36), did not translo-
cate with insulin-stimulation.
We next compared the intracellular localization of these proteins
with GLUT4. A defining feature of the intracellular localization of
GLUT4 is its concentration in peripheral vesicles that are thought to
represent the insulin-responsive vesicles (37). Our laboratory has pre-
viously described quantitative immunoelectron microscopic labeling of
basal versus insulin-treated 3T3-L1 and primary rat adipocytes (4, 37).
We observed a 53% reduction in GLUT4 labeling of cytosolic vesicles in
response to insulin, whereas only an 18% reduction in GLUT4 labeling
was seen for theTGNor perinuclear region. These data indicate that the
peripheral cytosolic vesicles correspond to the insulin-responsive
GSVs. In agreement with this conclusion, we observed significant co-
localization between GLUT4, IRAP, and VAMP2 in cytosolic vesicles
(Fig. 2A). However, this was not the case for any of the other integral
membrane proteins examined. For example some proteins such as sor-
tilin (Fig. 2A) and syntaxin 16 (data not shown) were highly concen-
trated in the perinuclear area, presumably corresponding to TGN label-
ing, butwere not concentrated in the peripheral cytosolic vesicles. Some
proteins like the copper-transporting ATPase ATP7A (Fig. 2A) or
VAMP3 (data not shown) exhibited both perinuclear and peripheral
cytosolic vesicular staining (Fig. 2A). However, the peripheral cytosolic
vesicular staining did not correspond to that containing GLUT4, indi-
cating that these proteins reside in separate vesicles. Therefore, these
studies indicate that the major integral membrane proteins in GSVs are
GLUT4, IRAP, and VAMP2.
Characterization of Peripheral Membrane Proteins Found in GLUT4
Vesicles—Several novel peripheral membrane proteins were discovered
associated with GLUT4 vesicles in this study by mass spectrometry.
Perhaps the most interesting among these were 3 Rab proteins Rab10,
Rab11, Rab14, and the RabGAPAS160. Rab11 has previously been stud-
ied in the context of GLUT4 trafficking, but there is little evidence to
indicate a role for this protein in the insulin-regulated trafficking of
GSVs to the PM (11). In contrast, Rab10 and Rab14 have not previously
been described in GLUT4 vesicles. To verify our mass spectrometry
data, we obtained antibodies against Rab11 and Rab14; however, no
Rab10-specific antibodies are currently available. We immunoblotted
GLUT4 vesicles isolated from adipocytes that had been incubated in the
absence or presence of insulin and found that both Rab11 and Rab14
remained associated with the GLUT4 vesicles with and without insulin
stimulation (Fig. 3). Rab7, which had been found to non-specifically
associate with GLUT4 vesicles in themass spectrometry analysis, is also
shown (Fig. 3). Rab5, which has previously been shown not to associate
with GLUT4 vesicles (38), was neither detected in the control nor in
GLUT4 immuno-isolations (Fig. 3). We next wanted to examine the
intracellular localization of the Rabs using confocal immunofluores-
TABLE ONE—CONTINUED
A Entry name as shown in the Swiss-prot and Trembl databases.
B Accession number as shown in the Swiss-prot and Trembl databases.
C Overlap of protein with GLUT4 in the perinuclear area of unstimulated 3T3-L1 adipocytes.
D Overlap of protein with GLUT4 in the peripheral cytosolic area of unstimulated 3T3-L1 adipocytes.
E Translocation of proteins to the plasma membrane of 3T3-L1 adipocytes treated with 100 nM insulin for 30 min.
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cence microscopy. To accomplish this we attempted to localize the
endogenous Rab proteins because overexpression of Rab proteins has
been shown to impair endogenous trafficking pathways (39). Only
Rab14 antibodies gave specific labeling in adipocytes. Rab14 displayed
punctate staining in the periphery of the cell and perinuclear staining as
previously described in other cell types (19) (Fig. 2B). When the co-
localization of Rab14 with GLUT4 was studied we found some overlap
in peripheral GLUT4 vesicles and in the perinuclear region correspond-
ing to the Golgi/TGN (Fig. 2B). However, co-localization in peripheral
GLUT4-containing vesicles was not as significant as that seen for IRAP
and VAMP2.
The identification of AS160 on the samemembranes as the three Rab
proteins was particularly interesting and raises the possibility that they
may be in vivo substrates for the GAP activity of AS160. To examine the
function of AS160 in GLUT4 trafficking, we generated a rabbit poly-
clonal antibody against a central region of AS160. Consistent with pre-
vious studies by Sano et al. (40), our antibody against AS160 specifically
recognizes immunoprecipitated FLAG-tagged AS160 (Fig. 4A). This
antibody also immunolabeled a protein of 160 kDa in adipocytes that
were enriched in the LDM fraction (Fig. 4B), which contains the major-
ity of GLUT4 vesicles (22). We have previously shown that the LDM
fraction is comprised of bothmembrane vesicles and large protein com-
plexes (24). To clarify which structures AS160 is associated with in the
LDM, we subjected this fraction to sucrose density flotation analysis.
Intriguingly, although themajority of AS160 was found at the bottom of
the gradient, a significant amount was found in the vesicle-enriched
fraction, migrating at a similar position toGLUT4. To confirm themass
spectrometry data showing the association of AS160 with GLUT4 ves-
icles, we immunoblotted purified GLUT4 vesicles with the AS160 anti-
body. Consistent with the mass spectrometry data, AS160 was detected
in the GLUT4 vesicles but was not detected in control IgG samples. In
addition, we found that insulin stimulation induced a marked decrease
in the amount of AS160 associated with GLUT4 vesicles (Fig. 4D). The
dissociation of AS160 from GLUT4 vesicles was blocked by treatment
with the phosphatidylinositol 3-kinase inhibitor wortmannin before
insulin stimulation (Fig. 4E).
Identification of IRAP as the Binding Partner for AS160 on GLUT4
Vesicles—The above data are consistent with a model whereby the
interaction of AS160 with GLUT4 vesicles plays a key role in their intra-
cellular sequestration in the basal state. Therefore, we next wanted to
identify the molecular basis for this interaction. In view of our data
showing that GLUT4, IRAP, and VAMP2 are the major integral mem-
brane proteins in GLUT4 vesicles, we next explored the possibility that
AS160 may interact with one or more of these proteins. To test this we
performed in vitroGSTpull-down experiments using lysates fromCHO
IR/IRS-1 cells that had been transiently transfected with FLAG-tagged
AS160. As shown in Fig. 5A, whereas we were unable to observe any
specific binding of AS160 to GST alone, GST fused to the cytosolic tail
of VAMP2, or GST fused to the carboxyl tail of GLUT4, there was a
significant interaction between AS160 and the GST-IRAP1–109 fusion
protein (data not shown) and aGST-IRAP1–58 fusion protein (Fig. 5A).
In contrast, we were unable to observe an interaction between AS160
and a truncated IRAP cytosolic tail comprising the first 27 amino acids
(Fig. 5A). Moreover, the interaction between AS160 and the IRAP tail
was significantly higher using basal compared with insulin-treated cell
lysate. To further confirm this interaction, we next endeavored to show
an interaction between AS160 and IRAP in vivo. LDM was prepared
from basal or insulin-stimulated 3T3-L1 adipocytes and solubilized in
60 mM -octylglucoside, 1% Triton X-100, and the soluble fraction was
incubated with either control antibodies or antibodies against AS160 or
FIGURE 1. Translocation of GLUT4 vesicle proteins identified bymass spectrometry
to the plasma membrane with insulin-stimulation in 3T3-L1 adipocytes. Plasma
membranes were isolated for each condition using the cationic silica isolation method.
A, translocation of GLUT4 and syntaxin 4 to the plasma membrane after 2 or 30 min of
stimulation with 100 nM insulin or 30 min with 100 nM wortmannin before a 30-min
stimulation with 100 nM insulin. Protein levels were detected by immunoblotting. B,
translocation of proteins to the plasma membrane after 30 min of stimulation with 100
nM insulin. C, quantification of protein translocation to the plasma membrane with 100
nM insulin stimulation for 30 min. Error bars are S.E. Immunoblots are from a representa-
tive experiment (n	 4).
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IRAP coupled to CNBr beads. As shown in Fig. 5B, IRAP co-immuno-
precipitated with AS160, and this interaction was only observed in basal
but not in insulin-stimulated cells. Similarly, AS160 co-immunoprecipi-
tated with IRAP from adipocyte lysate, but in contrast to that observed
in the AS160 immunoprecipitate, this interaction was only slightly
reduced by insulin (Fig. 5C). The explanation for this difference is not
clear; however, these data suggest that the effect of insulin on the inter-
action between AS160 and IRAP may be more complex than a simple
dissociation event.
Co-localization of AS160withGLUT4andCharacterization of AS160
shRNA Knockdown—To further characterize AS160 in 3T3-L1 adipo-
cytes, we determined the co-localization of AS160 with GLUT4 by con-
focal immunofluorescence microscopy. AS160 showed a predomi-
nantly peripheral vesicular staining pattern (Fig. 2B). Co-localization of
AS160 with GLUT4 indicated some overlap of the two proteins in
peripheral vesicles and the perinuclear area (Fig. 2B). The insulin-de-
pendent release of AS160 from vesicles suggests a model whereby the
targeting of AS160 to GLUT4 vesicles in the absence of insulinmay play
an important role in the intracellular sequestration of this compart-
ment. To test this we used RNA interference to suppress the expression
of AS160. We constructed a hairpin vector specifically targeting AS160
that was able to suppress AS160 levels by greater than 80% after tran-
sient transfection in C2C12 cells (Fig. 6A). To express the shRNA in
insulin-responsive adipocytes we employed the pBabe retrovirus. As
indicated in Fig. 6A adipocytes infected with this retrovirus demon-
strated a 40% reduction in AS160 protein levels. To measure GLUT4
translocation in cells in which AS160 levels were suppressed, we co-
infected cells with retroviruses expressing HA-GLUT4 and AS160
shRNA. Because of the variable reduction in AS160 levels, we used a
single cell analysis to study the relationship between total AS160 expres-
sion and cell surface levels of HA-GLUT4. This analysis revealed that
overall, cells infected with the AS160 shRNA had an 8-fold increase in
surface HA-GLUT4 labeling compared with control cells (p  0.005).
Analysis of the individual data points clearly indicates that there is a
threshold level of AS160 expression, below which surface levels of HA-
GLUT4 are significantly elevated. Importantly, the increase in PM levels
FIGURE 2. Localization of integral and periph-
eral membrane proteins with GLUT4. 3T3-L1
adipocytes were serum-starved for 2 h and fixed
and processed for immunofluorescence. GLUT4
was detected using a Cy3-conjugated secondary
antibody, and the other proteins shown were
detected using ALEXA 488-conjugated secondary
antibodies. A, co-localization of GLUT4 vesicle
integral membrane proteins with GLUT4 vesicles
in the basal state. B, co-localization of GLUT4 vesi-
cle peripheral membrane proteins with GLUT4
vesicles in the basal state. Images are from a rep-
resentative experiment (n	 3).
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of HA-GLUT4 upon reduced AS160 expression were similar to that
observed in control cells treated with insulin (Fig. 6B). It has previously
been shown that overexpression of the AS160 4P mutant in adipocytes
principally affects GLUT4 translocation by perturbing the exocytosis of
GLUT4 (41). We wanted to determine whether the AS160 shRNA was
functioning in a similar manner. To determine this, recycling experi-
ments were performed in which either control cells or cells expressing
theAS160 shRNAwere incubatedwith anti-HA antibody at 37 °C for 10
min or 60min. As shown in Fig. 6C in non-stimulated control cells there
was little antibody uptake over the course of the 60-min incubation,
consistent with previous studies showing that the basal recycling rate of
HA-GLUT4 is very slow (6, 42). In contrast, in cells expressing the
AS160 shRNA there was a significant increase in antibody uptake even
in the absence of insulin, and labeling was detected at an intracellular
localization consistent with increased exocytosis of GLUT4 upon
AS160 reduction.
DISCUSSION
In this study we have made several novel observations about insulin-
regulatedGLUT4 trafficking in adipocytes. First, using a comprehensive
proteomic and biochemical analysis of affinity-purified GLUT4 vesicles
we have found that the major membrane protein constituents of GSVs
are GLUT4, IRAP, and VAMP2. The remaining constituents are prob-
ably endosomal or TGN-derived proteins. Second, we have identified
three Rab proteins associated with GLUT4 vesicles, Rab10, Rab11, and
Rab14, two of which have not previously been reported to associate with
GLUT4 vesicles. Third, we have shown that the putative RabGAP
AS160 is associated with GLUT4 vesicles in 3T3-L1 adipocytes and
dissociates from GLUT4 vesicles with insulin stimulation. Fourth, we
have demonstrated that the binding of AS160 to GLUT4 vesicles in the
basal state is mediated at least in part via an interaction with the integral
membrane protein IRAP and that this interaction is insulin-regulated.
Finally, we show that knockdown of AS160 in adipocytes with shRNA
causes insulin-independent movement of GLUT4 to the PM.
Previous studies attempting to identify proteins associated with
GLUT4 vesicles used analytical techniquesmuch less sensitive than that
used in the present study and have, therefore, only identified the most
abundant proteins. The proteins identified previously include GLUT4,
IRAP (43), VAMP2 (44), TfR (45), CD-MPR (37), CI-MPR (46), sortilin
(35), copper amine oxidase (34), SCAMPs (47), andVAMP3 (for review,
see Bryant et al. (1)). We have identified all of these proteins and many
other novel proteins not previously identified in GLUT4 vesicles. The
large number and the diverse localizations of the proteins identified
demonstrate that we have achieved a comprehensive analysis of the
majority of proteins associatedwithGLUT4 vesicles. Based on ourmor-
phological and biochemical analysis of a large number of these proteins,
we have concluded that GLUT4, IRAP, and VAMP2 are the major pro-
teins that are uniquely targeted to peripheral GLUT4 vesicles in adipo-
cytes, and these studies likely explain the unique responsiveness of these
FIGURE 3. Rab proteins associate with immuno-isolated GLUT4 vesicles. The LDM
fraction and a control andGLUT4 vesicle immuno-isolation eluate purified from the LDM
fraction of 3T3-L1 adipocytes were immunoblotted for the presence of Rab proteins.
These fractions were purified from 3T3-L1 adipocytes that had been incubated in the
absence () or presence () of 100 nM insulin for 30min. Protein levelswere detected by
immunoblotting with specific antibodies and visualized by chemiluminescence. Immu-
noblots are from a representative experiment (n	 4). IP, immunoprecipitated.
FIGURE 4. AS160 associates with GLUT4 vesicles in the basal state and dissociates
with insulin stimulation in 3T3-L1 adipocytes. A, FLAG-tagged AS160 was overex-
pressed in CHO cells and immunoprecipitated (IP) using a monoclonal anti-FLAG anti-
body. Control and FLAG-AS160 lysates and FLAG immunoprecipitates were immuno-
blotted with the AS160 antibody. B, 3T3-L1 adipocytes incubated in the absence () or
presence () of 100 nm insulin for 30 min were fractionated to generate cytosol (Cyto),
PM, LDM, high density microsome, mitochondria, and nuclei (M/N). AS160 levels were
detected by immunoblotting with the AS160 polyclonal antibody. C, 3T3-L1 adipocytes
in the basal statewere fractionated to obtain the LDM fraction, whichwas then analyzed
by sucrose density flotation. The pellet and fractions 1–11, which represent the bottom
and the top of the sucrose gradient, respectively, were then analyzed by immunoblot-
ting.D, the LDM fraction and a control and GLUT4 vesicle immuno-isolation eluate puri-
fied from the LDM fraction of 3T3-L1 adipocytes were immunoblotted for the presence
of GLUT4, IRAP, VAMP2, and AS160. These fractions were purified from 3T3-L1 adipo-
cytes thathadbeen incubated in theabsence () or presence () of 100nm insulin for 30
min. E, GLUT4 vesicle immuno-isolation eluate purified from the LDM fraction of 3T3-L1
adipocytes were immunoblotted for the presence of GLUT4 and AS160. These fractions
were purified from 3T3-L1 adipocytes that had been incubated in the absence () or
presence () of 100 nM insulin for 30 min or incubated with 100 nM wortmannin for 30
min before incubation with 100 nM insulin for 30 min. Protein levels were detected by
immunoblotting with specific antibodies and visualized by chemiluminescence. Immu-
noblots are from a representative experiment (n	 4).
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proteins. Notably, insulin also has a smaller effect on the translocation
of other proteins including the TfR (Fig. 1b) and GLUT1 (48). There are
at least three possible explanations for this effect (1). First, insulin may
inhibit general endocytosis. This is unlikely because it has been shown
that insulin has no effect on TfR endocytosis in adipocytes (49). Second,
a small proportion of the TfR may be targeted to GSVs and undergo
exocytosis together with GLUT4, VAMP2, and IRAP. However, Akt is
not involved in TfR exocytosis, which suggests that the mechanism for
its regulated release is different compared with these other proteins
(50). Third, insulinmay increase endosomal recycling. This seems likely
because a number of endosomal recycling proteins including MPR,
GLUT1, andTfR have been shown to undergo a relatively small increase
in translocation to the PM with insulin (1). We cannot rule out that
some of the other proteins identified for which we do not have antibod-
ies may be in GSVs. However, studies of synaptic vesicle proteins have
also shown that synaptic vesicles are quite simple in composition, as
their sole role is the stimulated release of neurotransmitter (51). How-
ever, similar to this study, low levels of other proteins not crucial for
synaptic vesicle exocytosis, such as Vti1A and SCAMPs, are also found
in purified synaptic vesicles. This suggests the idea that such factors
arise from the recycling of small synaptic vesicles through endosomes or
the TGN (52, 53). Two proteins that we have identified that may be
worthy of future study are the marvel domain-containing proteins pro-
teolipid protein 2 and the myeloid-associated differentiation marker.
Proteins containing this domain have been shown to regulate vesicle
trafficking, but their exact role is not clear (54). Most of the other pro-
teins found in the purified GLUT4 vesicles are involved or associated
with GLUT4 recycling within endosomes or the TGN. This minimal
GSV translocation system is consistent with previous electron micros-
copy studies of GLUT4 vesicles in adipocytes (37), which showed the
majority of GLUT4 is recruited to the PM from vesicles that do not
contain recyclingmembrane proteins such as CD-MPR. It also supports
a growing number of studies that suggest the majority of regulatory
factors involved in vesicle transport, aside from cargo and SNAREs, are
peripherally associated cytosolic factors such as coat proteins or Rab
proteins.
Previous studies have tried to examine which Rab proteins play a role
in GLUT4 trafficking, but only Rab4 and Rab11 have been implicated in
insulin-stimulated GLUT4 vesicle translocation (11, 14, 15). Expression
of a dominant negative mutant of Rab4 in adipocytes inhibits GLUT4
translocation by50%, and the only direct evidence of a role for Rab4 in
GLUT4 translocation is its binding to syntaxin 4 (14). However, the
significance of this observation is not clear, as Rab proteins have not
been found to bind directly to t-SNAREs in other vesicle transport path-
ways. Moreover, we failed to observe Rab4 in our GLUT4 vesicle frac-
tion, suggesting that the majority of Rab4 probably does not co-localize
with GLUT4 in adipocytes. Rab11 is known to be involved in traffic
through recycling endosomes, and it has previously been shown to be
associated with GLUT4 vesicles (11). Rab11 translocates to the PM
slightly with insulin stimulation (11). However, Rab11 does not translo-
cate to the PMwithGTPS stimulation, indicating that the PMmay not
be the Rab11 target organelle (13). Rab11 function has been implicated
in insulin-stimulated GLUT4 translocation through interactions with
Rab11bp (55). However, themechanism of action of Rab11 is unknown.
The discovery in this study that Rab10, Rab11, and Rab14 are associated
withGLUT4 vesicles is exciting, because one ormore of these three Rab
proteins may be substrates for the RabGAP AS160 and play an integral
role in insulin action. Rab14 has been shown to be involved in TGN to
endosomal trafficking (19); however, significant amounts of Rab14 are
found at the PM. Therefore, Rab14 may have other more specialized
roles in exocytosis such as insulin-stimulated GLUT4 translocation.
The role of Rab10 has yet to be elucidated. Intriguingly, it is one of the
closest mammalian homologues of the yeast sec4 protein (56) and,
therefore, may function in the post-Golgi secretory pathway. Sec4 has
been shown to regulate assembly of the tethering complex known as the
exocyst (57). This is of interest because the exocyst has been implicated
in insulin-regulated GLUT4 trafficking in adipocytes (58). Amino acid
sequence alignment of the three Rab proteins identified in this study
shows that Rab14 and Rab11 are much more closely related to each
other than to Rab10, which may indicate that Rab10 has a more unique
role in GLUT4 exocytosis. Further work will be required to examine the
role of each Rab in GSV translocation and their association with AS160.
Intriguingly, Lienhard and co-workers (59) have recently shown in an in
vitro GAP assay that the GAP domain of AS160 shows GAP activity
toward Rab10 and Rab14.
Recently, we and others have suggested that themovement ofGLUT4
vesicles toward the PM is Akt-independent, whereas a step close to the
PM, likely involving docking and/or fusion of GLUT4 vesicles, is the
major Akt-dependent step (7, 9, 40, 41, 60). In this study we have shown
that AS160 dissociates from GLUT4 vesicles with insulin stimulation.
Furthermore, we have shown that there is a specific association between
AS160 and the cytosolic tail of IRAP. This observation is intriguing for a
number of reasons. First, it has previously been shown that microinjec-
tion of a fusion protein comprising the cytosolic N terminus of IRAP
into adipocytes was sufficient to triggerGLUT4 translocation to the PM
(61). A similar effect was observed using a fusion protein encompassing
the first 58 amino acids of the IRAP tail, and we have also observed that
this peptide interacts with AS160 in vitro. Hence, it is tempting to spec-
ulate that overexpression of the IRAP cytosolic tail in adipocytes blocks
FIGURE5. Identificationof IRAPas thebindingpartner forAS160onGLUT4vesicles.
A, CHO cells overexpressing FLAG-AS160 were incubated in the absence or presence of
insulin (100 nM) for 15min. Cellswere lysed and incubatedwithGST alone, GST-GLUT4CT,
GST-VAMP21–94, GST-IRAP1–27, and GST-IRAP1–58 coupled to CNBr-activated Sepharose
4B Beads. AS160 in the GST pull-down was detected with anti-FLAG antibody. B and C,
3T3-L1 adipocytes were incubated in the absence or presence of insulin for 15 min, and
a LDM fraction was prepared. LDMwas dissolved in 1% Triton X-100 and 60mM -octyl-
glucoside, centrifuged at 200,000 g for 15min, and used for immunoprecipitation (IP)
with IgG control, IRAP, or AS160 antibodies. Immunoprecipitates were then immuno-
blottedwith antibodies specific for bothAS160and IRAP.Ø indicatesbeads-only control.
Immunoblots are from a representative experiment (n	 3).
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the interaction of AS160 with the GLUT4 vesicles, thus allowing their
constitutive translocation to the PM. Second, it has been shown that
GLUT4 trafficking is unaffected in adipocytes from IRAP knock out
mice, suggesting that IRAP is not necessary for the intracellular seques-
tration of the vesicles (62). A likely explanation for this is that AS160
may be capable of interacting with other proteins associated with
GLUT4 vesicles, possibly even its putative Rab substrate. Cargo binding
may be a general function of RabGAPs in view of the large number of
RabGAPs in the human genome, and one could envisage that if each
member of this family encoded unique cargo binding specificity, this
could represent a novel mechanism for regulating protein trafficking at
different locations in eukaryotic cells. Each cargo-RabGAP interaction
could be controlled by discrete signaling inputs. In the case of AS160,
this appears to involve phosphorylation by Akt, and as described above,
this would place the action of AS160 close to the PM. In this way the
dissociation of AS160 fromGSVsmay trigger GTP loading of a relevant
Rab protein. Although Rabs have been implicated at several steps in
vesicle transport, one of their major functions appears to involve regu-
lation of vesicle docking at the target membrane (63). The fact that the
down-regulation of AS160 led to insulin-independent movement of
GLUT4 to the PM indicates the involvement of AS160 before fusion. A
recent study by Zeigerer et al. (41) has also shown that a step before
GLUT4 vesicle fusion is AS160-dependent. These studies also suggest
that AS160 plays an important role in the intracellular sequestration of
GLUT4 in the absence of insulin. As reported previously (6, 26), GLUT4
has a very low rate of cell surface recycling in the absence of insulin as
indicated in Fig. 6C. Suppression of AS160 levels enhance this basal
recycling rate (Fig. 6C). This is unlikely due to an effect of AS160 on
endocytosis because we observed rapid internalization of GLUT4 in
cells expressing the AS160 shRNA. This is consistent with experiments
performed by Zeigerer and co-workers (41) showing that overexpres-
sion of the AS160 4P mutant inhibited GLUT4 exocytosis with no
effects on GLUT4 endocytosis. These studies are consistent with a role
of AS160 in GLUT4 exocytosis. This demonstrates that AS160 is a spe-
cific regulator for the exocytosis of insulin-responsive GLUT4 vesicles
in adipocytes.We propose amodel of GLUT4 translocation such that in
the basal state AS160 is associated with GSVs by interacting with IRAP
and possibly other vesicle cargo, and its GAP activity maintains a key
GTPase(s) in an inactive GDP-bound form. Upon stimulation with
insulin the GSVsmove toward the PM, and AS160 is phosphorylated by
Akt, leading to its dissociation from GSVs. This allows GTP loading of
one or more Rab proteins, enabling the docking and fusion of the GSVs
with the PM.
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Table 2 - 3T3-L1 Adipocyte GLUT4 Vesicle Proteins 
LocusIDA (Accession No.) DescriptionB
Sequence 
Coverage 
(%)C Peptide SequencesD XcorrE
Vesicle transport proteins       
A2A1_MOUSE (P17426) Adapter-related protein complex 2 alpha 1 subunit 
(Alpha-adaptin A)  1.2   R.ACNQLGQFLQHR.E 3.18
A2A2_MOUSE (P17427) Adaptor-related protein complex 2 alpha 2 subunit 
(Alpha-adaptin C)  6.5   R.VVHLLNDQHLGVVTAATSLITTLAQK.N 2.24
      K.KGPSTVTDLEETKR.E 2.38 
DYL1_HUMAN (Q15701) Dynein light chain 1, cytoplasmic (8 kDa dynein light 
chain) (DLC8)  24.7   K.YNPTWHCIVGR.N 2.01
      R.NFGSYVTHETK.H 2.23 
O70404 (O70404) Vamp8 (Endobrevin) 22.8  K.NIMTQNVER.I 1.70
      R.NKTEDLEATSEHFK.T 3.16 
Q14677 (Q14677) Hypothetical protein KIAA0171 (Epsin 4) 2.1   K.GEFKDEEETVTTK.H 3.60
Q9ER00 (Q9ER00) Syntaxin 12 40.5  R.ISQATAQIK.N 2.31
      K.LQENLQQLQHSTNQLAK.E 3.26 
      K.ELGSLPLPLSASEQR.Q 2.99 
      R.LMNDFSSALNNFQVVQR.K 5.24 
      R.QLEADILDVNQIFK.D 4.33 
      K.DLAMMIHDQGDLIDSIEANVESSEVHVER.A 3.59 
Q9ERN0 (Q9ERN0) Secretory carrier membrane protein 2 4.3  K.ERELQNTAANLHVR.E 4.06
      R.ELQNTAANLHVR.E 3.04 
Q9JI56 (Q9JI56) SNAP-29 protein 4.3   K.SVFGGFINYFK.S 2.39
Q9JKK1 (Q9JKK1) Syntaxin 6  36.9   R.WTELLQGPSAATREEIDWTTNELR.N 3.63
      R.SIEWDLEDLDETISIVEANPR.K 4.85 
      R.KFNLDATELSIR.K 2.76 
      R.KFNLDATELSIRK.A 3.34 
      R.IGGELEEQAVMLDDFSHELESTQSR.L 3.15 
RB11A(B)_MOUSE (P62492) Ras-related protein Rab-11A/(P46638) Ras-related 
protein Rab-11B 11.5   R.GAVGALLVYDIAK.H 3.40
      K.HLTYENVER.W 2.80 
RB10_RAT (P35281) Ras-related protein Rab-10 11   K.LLLIGDSGVGK.T 2.13
      K.AFLTLAEDILR.K 3.00 
RB14_HUMAN (P35287) Ras-related protein Rab-14 13   R.STYNHLSSWLTDAR.N 3.25
      R.NLTNPNTVIILIGNK.A 2.93 
SCA3_MOUSE (O35609) Secretory carrier-associated membrane protein 3 19   R.TAAANAAAGAAENAFR.A 3.86
      R.ELQHVALGGAGTR.Q 2.46 
      R.ERELQHVALGGAGTR.Q 3.87 
      R.NYGSYSTQASAAAATAELLK.K 3.92 
      K.AQQEFAAGVFSNPAVR.T 2.67 
SNAA_MOUSE (Q9DB05) Alpha-soluble NSF attachment protein (SNAP-alpha)  
48.8   K.QAEAMALLAEAER.K 3.53
      K.NSQSFFSGLFGGSSK.I 3.51 
      K.IEEACEIYAR.A 2.17 
      K.NWSAAGNAFCQAAQLHLQLQSK.H 4.13 
      K.HHISIAEIYETELVDVEK.A 4.02 
      K.AALCHFCIDMLNAK.L 3.92 
      K.YEELFPAFSDSR.E 3.16 
      K.KLLEAHEEQNVDSYTEAVK.E 3.21 
      R.LDQWLTTMLLR.I 3.46 
      K.TIQGDEEDLR.- 2.08 
SNAG_MOUSE (Q9CWZ7) Gamma-soluble NSF attachment protein (SNAP-
gamma)  7.7   K.TIAQVLVHLHR.N 2.31
      K.LGLSLVVPGGGIK.K 2.72 
STXF_HUMAN (O14662) Syntaxin 16 (Syn16) 14.3  R.RLTDAFLLLR.N 2.61
      R.QLLAEQVSSHTTSSPLHSR.S 2.80 
      R.NVVASLAQALQELSTSFR.H 5.59 
VAM2_MOUSE (Q64357) Vesicle-associated membrane protein 2 (VAMP-2) 
(Synaptobrevin 2)  20.9   K.LSELDDRADALQAGASQFETSAAK.L 3.61
      R.ADALQAGASQFETSAAK.L 3.81 
VAM3_MOUSE (Q64271) Vesicle-associated membrane protein 3 (VAMP-3) 
(Cellubrevin)  39.8   R.RLQQTQNQVDEVVDIMR.V 2.74
      R.LQQTQNQVDEVVDIMR.V 5.22 
      K.LSELDDRADALQAGASQFETSAAK.L 3.62 
      R.ADALQAGASQFETSAAK.L 3.81 
VP45_MOUSE (P97390) Vacuolar protein sorting-associated protein 45 (mVps45) 
20.9   R.KLVSAVVEYGGKR.V 3.45
      R.LKENLYPYLGPSTLR.D 3.86 
      R.IVLGGTTIHNTK.S 2.35 
      K.SFLEEVLASGLHSR.S 3.03 
      K.AICFLRPTK.E 1.77 
      K.ENVEYLIQELR.R 3.04 
      R.TTQGLTALLLSLK.K 2.39 
      K.EYELFEFR.R 2.21 
      R.RTEVPPLLLILDR.C 3.38 
      R.TEVPPLLLILDR.C 3.00 
      R.LVMLYALHYER.H 2.79 
VT1B_MOUSE (O88384) Vesicle transport through interaction with t-SNAREs 
homolog 1B (Vesicle transport v-SNARE protein Vti1-like 1) (Vti1-
rp1) 13.4   R.STPLTAAPGGR.G 1.81
      R.IATETDQIGTEIIEELGEQR.D 3.51 
Proteins from the secretory pathway       
APM1_MOUSE (Q60994) Adiponectin precursor  9.7   R.GFPGTPGRK.G 2.13
      K.IFYNQQNHYDGSTGK.F 2.59 
CBPD_MOUSE (O89001) Carboxypeptidase D precursor (EC 3.4.17.-) (GP180) 10.9   K.FVLSGNLHGGSVVASYPFDDSPEHK.T 2.58
      R.ESLITLIEK.V 2.53 
      R.ELLLNLIEYLCK.N 3.88 
      K.NFGTDPEVTDLVR.S 2.83 
      K.SQEGDSISVVGR.N 2.71 
      R.NFPDQFVPITEPTQPETIAVMSWVK.A 3.78 
      K.RNPVVTQLVDR.T 2.87 
      R.IVIVPSLNPDGR.D 2.89 
      K.SLLSHEFQDETDTEEETLYSSK.H 5.86 
CYTC_MOUSE (P21460) Cystatin C precursor (Cystatin 3) 30  R.KALCSFQIYSVPWK.G 3.40
      R.ALDFAVSEYNK.G 3.07 
      R.KQLVAGVNYFLDVEMGR.T 3.56 
      K.ALCSFQIYSVPWK.G 3.99 
RSN_MOUSE (Q99P87) Resistin precursor  22.8   K.IKQDFNSLFPNAIK.N 3.22
      K.NIGLNCWTVSSR.G 2.49 
      R.WSELAGCTADFR.N 2.30 
Recycling 
membrane 
proteins 
  
      
AT7A_MOUSE (Q64430) Copper-transporting ATPase 1 (EC 3.6.3.4) (Copper 
pump 1) (Menkes disease-associated protein homolog) 3.2   K.AHIKYDPEIIGPR.D 3.69
      K.LGAIDVER.L 1.79 
      K.TGTITHGTPVVNQVK.V 3.43 
      R.KPTYDNYELHPR.S 3.10 
CD36_MOUSE (Q08857) Platelet glycoprotein IV (GPIV) (GPIIIB) (CD36 antigen)  11.3   R.EVVLEEGTTAFK.N 2.40
      R.FVLPANAFASPLQNPDNHCFCTEK.V 3.59 
      R.TYLDVEPITGFTLQFAK.R 2.45 
LDLR_MOUSE (P35951) Low-density lipoprotein receptor precursor (LDL 
receptor) 2.8   R.LTGSDVNLVAENLLSPEDIVLFHK.V 3.41
LDVR_MOUSE (P98156) Very low-density lipoprotein receptor precursor (VLDL 
receptor) 2.5   K.SLEFLAHPLALTIFEDR.V 3.38
      K.LFWADLSQK.A 2.56 
LIPL_MOUSE (P11152) Lipoprotein lipase precursor (EC 3.1.1.34) (LPL) 23.6   K.TFVVIHGWTVTGM*YESWVPK.L 3.01
      R.EPDSNVIVVDWLYR.A 2.93 
      R.AQQHYPVSAGYTK.L 2.80 
      R.LSPDDADFVDVLHTFTR.G 3.92 
      R.SIGIQKPVGHVDIYPNGGTFQPGCNIGEAIR.V 3.36 
      R.SIHLFIDSLLNEENPSK.A 2.84 
GTR1_MOUSE (P17809) Solute carrier family 2, facilitated glucose transporter, 
member 1 (GLUT1) 11.2   R.FLLINRNEENRAK.S 2.10
      K.VTILELFR.S 2.08 
      R.TFDEIASGFR.Q 2.56 
      R.QGGASQSDKTPEELFHPLGADSQV.- 3.23 
MPRD_MOUSE (P24668) Cation-dependent mannose-6-phosphate receptor 
precursor (CD-MPR) 30.2   K.SCDLVGEKDKESKNEVALLER.L 3.15
      K.NEVALLER.L 2.41 
      K.SFESTVGQGSDTYSYIFR.V 5.02 
      R.RAVVMISCNR.H 2.56 
      R.AVVMISCNR.H 1.86 
      R.HTLAANFNPVSEER.G 4.76 
      R.GVGDDQLGEESEERDDHLLPM.- 2.56 
MPRI_MOUSE (Q07113) Cation-independent mannose-6-phosphate receptor 
precursor (CI-MPR) (Insulin-like growth factor II receptor)  26.1   K.TLGTPEFVTATDCVHYFEWR.T 4.46
      K.HDLNPLIK.L 2.24 
      R.DIDSLRDPSTQLR.V 3.53 
      R.VCPAGTAACLLK.G 1.91 
      K.GNQAFDVGRPK.E 2.03 
      R.YEVEWITEYACHR.D 4.07 
      K.RYDLSVLAR.H 3.67 
      R.HSESEQNWEAVDGSQAESEK.Y 5.79 
      K.YFFINVCHR.V 2.41 
      R.NCPEDAAVCAVDK.N 2.27 
      K.EKGHIQLSYTDGDDCGSDKK.I 3.88 
      K.GHIQLSYTDGDDCGSDKK.I 4.68 
      R.SDGCFYEFEWHTAAACVLSK.T 4.24 
      R.ATLITFLCDR.D 2.52 
      K.YYLNVCRPLNPVPGCDR.Y 3.94 
      K.YENHEGSLAETVSISNLGVAK.I 4.31 
      K.FLHQDIDSTR.G 2.38 
      R.KPWTAVDTSAYGK.R 4.31 
      R.STTIYFYCDR.T 2.26 
      R.TGATEHYLINVCK.S 4.00 
      K.VRDGPQWTDGVTVLQYVDGDLCPDK.I 5.90 
      R.DGPQWTDGVTVLQYVDGDLCPDK.I 3.73 
      R.FTCSDNQVNSR.P 2.53 
      K.SNTHDDCQVTNPSTGHLFDLSSLSGR.A  4.06
      R.LSYKDQVLQLVYENGSPCPSLSDLR.Y 2.66 
      K.VPVDGPPIDIGR.V 2.94 
      R.VTGPPIFNPVANEVYLNFESSTHCLADR.Y 3.00 
      R.LASMQLDYR.H 2.30 
      R.HQDEAVILSYVNGDPCPPETDDGEPCVFPFIYK.G 4.97 
      K.SYDECVLEGR.A 2.20 
      K.TANYDRDHEWGFCR.Q 3.08 
      R.MSAIIFTCDESEDIGRPQVFSEDR.G 3.67 
      R.LLSSLTGSWDFVHEGNSYFINLCQR.V  3.33
      R.VYKGPLDCSER.A 2.66 
      K.KSATGQVQVLGLVHTQK.L 5.80 
      K.SATGQVQVLGLVHTQK.L 4.13 
      K.TASSVIELTCAK.T 2.68 
      K.SFSLGEIYFK.L 2.33 
      K.SVSSTIFFHCDPLVK.D 3.04 
      K.VSKEEETDENETEWLMEEIQVPAPR.L 4.05 
      K.AEALSSLHGDDQDSEDEVLTVPEVK.V 5.66 
      R.GAEVESSQPLR.N 2.14 
      R.GAEVESSQPLRNPQR.K 2.28 
      K.LVSFHDDSDEDLLHI.- 3.69 
TFR1_MOUSE (Q62351) Transferrin receptor protein 1 (TfR1) (TR) (TfR) (Trfr) 22.1   R.SAFSNLFGGEPLSYTR.F 3.49
      K.EECVKLAETEETDKSETM*ETEDVPTSSRLYWADLK.T  3.15
      K.LAETEETDKSETMETEDVPTSSR.L 4.88 
      K.LNSIEFADTIK.Q 2.52 
      R.EAGSQKDESLAYYIENQFHEFK.F 3.59 
      K.DESLAYYIENQFHEFK.F 2.82 
      K.VANAQSFNAIGVLIYM*DK.N 1.90 
      R.RILNIFGVIK.G 2.85 
      R.ILNIFGVIK.G 2.28 
      K.GYEEPDRYVVVGAQR.D 2.86 
      K.SSVGTGLLLK.L 1.66 
      K.VEYHFLSPYVSPR.E 3.61 
      R.HIFWGSGSHTLSALVENLK.L 4.21 
VA0D_MOUSE (P51863) Vacuolar ATP synthase subunit d (EC 3.6.3.14)  13.4   K.FCTLLGGTTADAMCPILEFEADRR.A 2.75
      R.LYPEGLAQLAR.A 1.90 
      R.NIVWIAECIAQR.H 2.67 
VAA1_MOUSE (P50516) Vacuolar ATP synthase catalytic subunit A, (EC 
3.6.3.14)  5.8   R.VGSHITGGDIYGIVNENSLIK.H 4.49
      K.ADYAQLLEDMQNAFR.S 2.31 
VPP1_MOUSE (Q9Z1G4) Vacuolar proton translocating ATPase 116 kDa subunit 
A  1.9   R.RGTEHSGSTVPSILNR.M 3.94
Unknown 
vesicle transport 
functions 
  
      
CAV1_MOUSE (P49817) Caveolin-1 30.3   K.YVDSEGHLYTVPIR.E 2.83
      K.IDFEDVIAEPEGTHSFDGIWK.A 5.01 
      R.VYSIYVHTFCDPLFEAIGK.I 4.08 
CAV2_MOUSE (Q9WVC3) Caveolin-2 22.8   K.ADVQLFMADDAYSHHSGVDYADPEK.Y 3.50
      R.SFSSVSMQLSHD.- 2.11 
MYDM_MOUSE (O35682) Myeloid-associated differentiation marker  
10   R.TTITTTTSSSTTVGSAR.A 4.05
      R.SISYIQPNTVCFWDR.R 2.91 
Q63446 (Q63446) Ubiquitin  17.1  K.IQDKEGIPPDQQR.L 2.21
Q9R1Q7 (Q9R1Q7) Proteolipid protein 2 7.9   R.HTAAPTDPTDGP.- 3.19
STKG_MOUSE (O88697) Serine/threonine protein kinase 16 (EC 2.7.1.37) 
(Protein kinase PKL12) (Myristoylated and palmitoylated serine-
threonine kinase) (MPSK) (TGF-beta stimulated factor 1) (TSF-1) 
(Protein kinase Krct) 
15.5   R.ILCHEQQDQEEAQR.E 2.32
      K.HEAWLLLPFFK.K 3.16 
      R.LKDQGSFLTEDQILPLLLGISR.G 3.60 
TBC4_HUMAN (O60343) TBC1 domain family member 4 (AS160) 5.1  R.FIHNSHDLTYFAYLIK.A 4.56
      K.HVDHFGFICR.E 2.71 
      R.HLSSLTDNEQADIFER.V 4.65 
      R.RGEIWQFLALQYR.L 3.24 
      R.THVHIGEGPAIISNSTIPENVTSGGR.F 3.13 
      R.LWYVGGSCLDR.R 2.23 
Previously 
Known GLUT4 
Vesicle Proteins 
  
      
AOC3_MOUSE (O70423) Membrane copper amine oxidase (EC 1.4.3.6) (VAP-1) 
15.9   R.THPSQSQPFADLSPEELTAVMSFLTK.H 4.70
      R.HGGPLPYYR.R 2.94 
      R.ELPQASGLLHHCCFYK.H 3.22 
      K.HQGQNLLTM*TTAPR.G 2.80 
      K.SSVPPGPAPPLQFHPQGPR.F 2.37 
      R.KLLETEEEAAFPLGGATPR.Y 2.44 
      R.IQILSFAGKPLPQESPIEK.A 4.25 
GTR4_MOUSE (P14142) Solute carrier family 2, facilitated glucose transporter, 
member 4 (GLUT4) 19.8   R.FLIGAYSGLTSGLVPMYVGEIAPTHLR.G 5.00
      R.YLYIIR.N 1.65 
      K.RLTGWADVSDALAELKDEK.R 2.97 
      K.RLTGWADVSDALAELKDEKR.K 2.75 
      R.LTGWADVSDALAELK.D 3.72 
      R.LTGWADVSDALAELKDEK.R 3.81 
      R.LTGWADVSDALAELKDEKR.K 4.64 
      R.ERPMSLLQLLGSR.T 3.91 
      R.ERPM*SLLQLLGSR.T 3.73 
      R.TFDQISAAFR.R 2.79 
      R.RTPSLLEQEVKPSTELEYLGPDEND.- 4.42 
      R.TPSLLEQEVKPSTELEYLGPDEND.- 3.55 
Q8C129 (Q8C129) Insulin-regulated membrane aminopeptidase IRAP 
homolog 34.3  R.NMIENSMFEEEPDVVDLAKEPCLHPLEPDEVEYEPR.G 2.69
      K.EPCLHPLEPDEVEYEPR.G 2.85 
      R.GLGEHEMDEDEEDYESSAK.L 5.37 
      R.GLGEHEM*DEDEEDYESSAK.L 4.41 
      K.LLGMSFMNR.S 1.88 
      K.VFPWAQIR.L 1.54 
      R.VTFMSAVSSQEK.Q 2.28 
      K.KYFAATQFEPLAAR.S 3.23 
      K.YFAATQFEPLAAR.S 2.95 
      R.SAFPCFDEPAFK.A 2.65 
      R.NEHHTALSNMPK.K 2.76 
      K.KSSVPAEEGLIQDEFSESVK.M 4.55 
      K.SSVPAEEGLIQDEFSESVK.M 3.84 
      K.MSTYLVAFIVGEMR.N 1.78 
      K.IGQVHHALDTTIK.L 3.98 
      K.LLEFYQTYFEIQYPLK.K 4.22 
      K.ELNSYEDFLDAR.F 3.08 
      K.SYLSEDVFR.H 2.10 
      K.GFPLVTVQR.K 1.79 
      R.KGTELLLQQER.F 3.96 
      R.MQPESQPSDTSHLWHIPISYVTDGR.N 2.63 
      K.RNPYVLSDKDR.A 3.24 
      R.NPYVLSDKDR.A 3.10 
      R.ANLINNIFELAGLGK.V 3.75 
      K.LGHMDLSSR.L 1.78 
      K.LLQNQIQQQTWTDEGTPSMR.E 4.95 
      K.ILEALASSEDVHK.L 3.11 
      R.HFPGHLLAWDFVK.E 3.86 
      K.THLSEVQAFFENQSEATLK.L 5.87 
SORT_RAT (O54861) Sortilin (Glycoprotein 110) (Gp110) 6.5  K.NFGEKWEEIHK.A 1.83
      K.ADLGALELWR.T 2.97 
      R.QWVSYTVDFK.D 2.54 
      R.YSVLQQHAEADGVEALDSTSHAK.S 4.92 
VIME_MOUSE (P20152) Vimentin 36.6   R.M*FGGSGTSSRPSSNRSYVTTSTR.T 2.95
      R.TYSLGSALRPSTSR.S 1.73 
      R.SLYSSSPGGAYVTR.S 3.24 
      K.ILLAELEQLK.G 2.57 
      R.LGDLYEEEMR.E 3.03 
      R.EEAESTLQSFR.Q 1.83 
      R.QDVDNASLAR.L 2.77 
      R.KVESLQEEIAFLK.K 5.03 
      R.KVESLQEEIAFLKK.L 6.06 
      K.FADLSEAANR.N 2.49 
      R.EYQDLLNVK.M 1.74 
      R.ISLPLPTFSSLNLR.E 3.16 
      R.ETNLESLPLVDTHSK.R 3.48 
      R.DGQVINETSQHHDDLE.- 3.59 
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